Latest Breaking News On - Phathom pharmaceutical - Page 1 : comparemela.com

Biotech stocks are ready to break out They just need one more thing

Biotech stocks tend to outperform in the months leading up to an interest rate cut. But other factors are driving performance too.

Drug administrationBristol myers squibbGroup fedwatchMorgan stanleyRhythm pharmaceuticalsPhathom pharmaceuticalsRocket pharmaceuticalsFederal reserveFed fundsWall streetNasdaq biotechnology indexJoseph stringerRare diseasePhathom pharmaceuticalNew jersey basedIntellia therapeutics

With 47% ownership, Phathom Pharmaceuticals, Inc (NASDAQ:PHAT) has piqued the interest of institutional investors

Key Insights Given the large stake in the stock by institutions, Phathom Pharmaceuticals' stock price might be.

Phathom pharmaceuticalsInstitutional ownership tell us about phathom pharmaceuticalsPhathom pharmaceuticals incFrazier life sciences managementPublic company ownershipTakeda pharmaceutical companyMedicxi ventures united kingdomPhathom pharmaceuticalMedicxi venturesUnited kingdomTakeda pharmaceutical company limitedInstitutional investorsNsider ownershipInstitutional owners

FDA ends 2023 on high note for GI: Ulcerative colitis pipeline teeming with new approvals

FDA ends 2023 on high note for GI: Ulcerative colitis pipeline teeming with new approvals
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Eli lilly omvohBymonica stonehillZeposia ozanimodStates zymfentraRobert stottRedhill biopharmaEli lillyGilead sciencesTakeda pharmaceuticalsProcisedx incBristol myers squibbTakeda pharmaceutical entyvioCelltrion united statesPhathom pharmaceutical voqueznaVoquezna tripleDual pak

FDA Accepts NDA for Vonoprazan (Voquenza) in Non-Erosive GERD

The NDA submission was supported by positive data from the phase 3 PHALCON-NERD-301 study and has been assigned a standard 10-month review with a PDUFA target action date of July 19, 2024.

Azmi nabulsiDrug administrationPhathom pharmaceuticals announces positive toplinePhathom pharmaceuticalsPhathom pharmaceuticals announcesPhathom pharmaceuticals announces vonoprazanPhathom pharmaceuticalPrescription drug user fee actNew drug applicationTablets new drug applicationHeartburn associatedEvaluating daily dosingNon erosive gerdGastroesophageal reflux diseasePhalcon nerd 301Phase 3

Gastroenterology Month in Review: November 2023

November’s Gastroenterology Month in Review features an FDA approval, the discontinuation of a phase 3 clinical program, and news about Clostridioides difficile testing and risk factors.

North carolinaUnited statesData monitoring committeeKindex pharmaceuticalsPhathom pharmaceuticalData monitoringInduction studyCase safety reportsC diffClostridioides difficileErosive esophagitis